Langmead CJ - Search Results

1

Acetylcholine Muscarinic M₄ Receptors as a Therapeutic Target for Alcohol Use Disorder: Converging Evidence From Humans and Rodents.

Walker LC, Berizzi AE, Chen NA, Rueda P, Perreau VM, Huckstep K, Srisontiyakul J, Govitrapong P, Xiaojian J, Lindsley CW, Jones CK, Riddy DM, Christopoulos A, Langmead CJ, Lawrence AJ. Walker LC, et al. Among authors: langmead cj. Biol Psychiatry. 2020 Dec 15;88(12):898-909. doi: 10.1016/j.biopsych.2020.02.019. Epub 2020 Feb 29. Biol Psychiatry. 2020. PMID: 32331824

2

Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist.

Langmead CJ, Fry VA, Forbes IT, Branch CL, Christopoulos A, Wood MD, Herdon HJ. Langmead CJ, et al. Mol Pharmacol. 2006 Jan;69(1):236-46. doi: 10.1124/mol.105.017814. Epub 2005 Oct 5. Mol Pharmacol. 2006. PMID: 16207821

3

Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox.

Langmead CJ, Christopoulos A. Langmead CJ, et al. Trends Pharmacol Sci. 2006 Sep;27(9):475-81. doi: 10.1016/j.tips.2006.07.009. Epub 2006 Aug 4. Trends Pharmacol Sci. 2006. PMID: 16889837 Review.

4

Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.

May LT, Avlani VA, Langmead CJ, Herdon HJ, Wood MD, Sexton PM, Christopoulos A. May LT, et al. Among authors: langmead cj. Mol Pharmacol. 2007 Aug;72(2):463-76. doi: 10.1124/mol.107.037630. Epub 2007 May 24. Mol Pharmacol. 2007. PMID: 17525129

5

Muscarinic acetylcholine receptors as CNS drug targets.

Langmead CJ, Watson J, Reavill C. Langmead CJ, et al. Pharmacol Ther. 2008 Feb;117(2):232-43. doi: 10.1016/j.pharmthera.2007.09.009. Epub 2007 Dec 20. Pharmacol Ther. 2008. PMID: 18082893 Review.

6

Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor.

Avlani VA, Langmead CJ, Guida E, Wood MD, Tehan BG, Herdon HJ, Watson JM, Sexton PM, Christopoulos A. Avlani VA, et al. Among authors: langmead cj. Mol Pharmacol. 2010 Jul;78(1):94-104. doi: 10.1124/mol.110.064345. Epub 2010 Apr 22. Mol Pharmacol. 2010. PMID: 20413650

7

Supra-physiological efficacy at GPCRs: superstition or super agonists?

Langmead CJ, Christopoulos A. Langmead CJ, et al. Br J Pharmacol. 2013 May;169(2):353-6. doi: 10.1111/bph.12142. Br J Pharmacol. 2013. PMID: 23441648 Free PMC article.

8

Functional and structural perspectives on allosteric modulation of GPCRs.

Langmead CJ, Christopoulos A. Langmead CJ, et al. Curr Opin Cell Biol. 2014 Apr;27:94-101. doi: 10.1016/j.ceb.2013.11.007. Epub 2013 Dec 22. Curr Opin Cell Biol. 2014. PMID: 24680434 Review.

9

International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands.

Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP, Cidlowski JA, Olsen RW, Peters JA, Neubig RR, Pin JP, Sexton PM, Kenakin TP, Ehlert FJ, Spedding M, Langmead CJ. Christopoulos A, et al. Among authors: langmead cj. Pharmacol Rev. 2014 Oct;66(4):918-47. doi: 10.1124/pr.114.008862. Pharmacol Rev. 2014. PMID: 25026896

10

Label-Free Kinetics: Exploiting Functional Hemi-Equilibrium to Derive Rate Constants for Muscarinic Receptor Antagonists.

Riddy DM, Valant C, Rueda P, Charman WN, Sexton PM, Summers RJ, Christopoulos A, Langmead CJ. Riddy DM, et al. Among authors: langmead cj. Mol Pharmacol. 2015 Oct;88(4):779-90. doi: 10.1124/mol.115.100545. Epub 2015 Aug 4. Mol Pharmacol. 2015. PMID: 26243731

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

135 results

Search Page